ATOSNasdaqPharmaceutical PreparationsFiscal year ends December 31
ATOSSA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.56−0.35 (-12.03%)
Close on Oct 19, 2026
- Market cap
- $22.81M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$12.13 (−82.58%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $22.81M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.85
- Dividend yield
- –
- Free cash flow yield
- -156.90%
Fundamentals
- Net income
- -$37.71M
- EPS, diluted
- -$4.38
- Free cash flow
- -$35.78M
- Book value per share
- $3.01
- Diluted shares
- 9M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$39.25M
Net income
-$37.71M
EPS, diluted
-$4.38
Free cash flow
-$35.78M
Reported periodTrailing twelve months